{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:58:46Z","timestamp":1789016326695,"version":"build-2803163510"},"reference-count":54,"publisher":"Impact Journals, LLC","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2021,7,20]]},"DOI":"10.18632\/oncotarget.27973","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T15:23:43Z","timestamp":1626794623000},"page":"1555-1563","source":"Crossref","is-referenced-by-count":53,"title":["Developing next generation immunomodulatory drugs and their combinations in multiple myeloma"],"prefix":"10.18632","volume":"12","author":[{"given":"Anjan","family":"Thakurta","sequence":"first","affiliation":[{"name":"Translational Medicine, Bristol Myers Squibb, Summit, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Pierceall","sequence":"additional","affiliation":[{"name":"Translational Medicine, Bristol Myers Squibb, Summit, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Amatangelo","sequence":"additional","affiliation":[{"name":"Translational Medicine, Bristol Myers Squibb, Summit, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Flynt","sequence":"additional","affiliation":[{"name":"Translational Medicine, Bristol Myers Squibb, Summit, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Bristol Myers Squibb, Summit, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.bmcl.2012.10.071","article-title":"Isosteric analogs of lenalidomide and pomalidomide: synthesis and biological activity","volume":"2","author":"Muller","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"2","author":"Ito","year":"2014","journal-title":"Nat Struct Mol Biol"},{"key":"3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"51","author":"Forrester","year":"2014","journal-title":"Nature"},{"key":"4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos","volume":"6","author":"Riley","year":"2018","journal-title":"J Med Chem"},{"key":"5","doi-asserted-by":"publisher","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma","volume":"6","author":"Tang","year":"2020","journal-title":"J Med Chem"},{"key":"6","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"3","author":"Thakurta","year":"2020","journal-title":"Leukemia"},{"key":"7","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Daniel","year":"2015","journal-title":"Blood Cancer J"},{"key":"8","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1128\/MCB.00224-10","article-title":"Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression","volume":"3","author":"Lu","year":"2010","journal-title":"Mol Cell Biol"},{"key":"9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1023\/a:1015372322419","article-title":"Aiolos and Ikaros: regulators of lymphocyte development, homeostasis and lymphoproliferation","volume":"7","author":"Rebollo","year":"2002","journal-title":"Apoptosis"},{"key":"10","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"11","author":"Stewart","year":"2011","journal-title":"Blood"},{"key":"11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"34","author":"Munshi","year":"2014","journal-title":"Science"},{"key":"12","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1182\/blood-2010-10-314278","article-title":"IMiD immunomodulatory compounds block C\/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM","volume":"11","author":"Lentzsch","year":"2011","journal-title":"Blood"},{"key":"13","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"2","author":"Rychak","year":"2012","journal-title":"Leukemia"},{"key":"14","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","article-title":"SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate","volume":"1","author":"Fang","year":"2018","journal-title":"Nat Chem Biol"},{"key":"15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/156800910791054239","article-title":"Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function","volume":"1","author":"Hampton","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"key":"16","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"16","author":"Daniel","year":"2014","journal-title":"Br J Haematol"},{"key":"17","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway","volume":"10","author":"Munshi","year":"2004","journal-title":"Blood"},{"key":"18","doi-asserted-by":"publisher","first-page":"98200","DOI":"10.18632\/oncotarget.21516","article-title":"Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28\u2212 T-cells","volume":"8","author":"Hundemer","year":"2017","journal-title":"Oncotarget"},{"key":"19","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1124\/jpet.102.048496","article-title":"Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs","volume":"30","author":"Stirling","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"20","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1182\/blood-2018-99-113383","article-title":"Iberdomide (CC-220) has synergistic anti-tumor and immunostimulatory activityagainst multiple myeloma in combination with both bortezomib and dexamethasone, or in combination with daratumumab","volume":"13","author":"Thakurta","year":"2018","journal-title":"Blood"},{"key":"21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1182\/blood-2020-137710","article-title":"Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001","volume":"13","author":"Minnema","year":"2020","journal-title":"Blood"},{"key":"22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood-2020-137743","article-title":"First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"13","author":"Campagnaro","year":"2020","journal-title":"Blood"},{"key":"23","unstructured":"Soni, Baturevych, Works, Qin, Balakrishnan, Ports. Iberdomide Increases the Potency of the Anti-BCMA CAR T Cell Product Orvacabtagene Autoleucel (orva-cel). American Society of Gene and Cell Therapy (ASGCT) 23rd Annual Meeting 2020. https:\/\/asgct.org\/global\/documents\/asgct20_abstracts_may8?_zs=S2i4b&_zl=U9052."},{"key":"24","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1182\/blood-2019-124345","article-title":"CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma","volume":"13","author":"Pierce","year":"2019","journal-title":"Blood"},{"key":"25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"13","author":"Bahlis","year":"2021","journal-title":"Blood"},{"key":"26","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/leu.2013.315","article-title":"Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy","volume":"2","author":"Orlowski","year":"2014","journal-title":"Leukemia"},{"key":"27","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.3324\/haematol.2017.186601","article-title":"Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients","volume":"10","author":"Faber","year":"2018","journal-title":"Haematologica"},{"key":"28","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"12","author":"Jauch","year":"2016","journal-title":"Blood"},{"key":"29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1182\/blood.V128.22.120.120","article-title":"Cereblon Splicing of Exon 10 Mediates IMiDs Resistance in Multiple Myeloma: Clinical Validation in the CoMMpass Trial","volume":"12","author":"Bahlis","year":"2016","journal-title":"Blood"},{"key":"30","doi-asserted-by":"publisher","first-page":"8006","DOI":"10.1200\/JCO.2019.37.15_suppl.8006","article-title":"First clinical (phase 1b\/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"3","author":"Sonneveld","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/bmt.2009.155","article-title":"Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells","volume":"4","author":"Blaise","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"32","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1158\/1078-0432.CCR-11-1221","article-title":"Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses","volume":"1","author":"Borrello","year":"2012","journal-title":"Clin Cancer Res"},{"key":"33","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-20-1781","article-title":"Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed\/Refractory Multiple Myeloma","volume":"2","author":"Thakurta","year":"2020","journal-title":"Clin Cancer Res"},{"key":"34","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1182\/blood-2014-11-611426","article-title":"Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets","volume":"12","author":"Hansel","year":"2015","journal-title":"Blood"},{"key":"35","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1182\/blood-2018-99-111823","article-title":"Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone","volume":"13","author":"Brown","year":"2018","journal-title":"Blood"},{"key":"36","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/bloodadvances.2020002037","article-title":"Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma","volume":"4","author":"Wolf","year":"2020","journal-title":"Blood Adv"},{"key":"37","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1182\/blood-2019-124298","article-title":"Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)","volume":"13","author":"Bringhen","year":"2019","journal-title":"Blood"},{"key":"38","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"35","author":"Patin","year":"2007","journal-title":"N Engl J Med"},{"key":"39","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"35","author":"Olesnyckyj","year":"2007","journal-title":"N Engl J Med"},{"key":"40","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"12","author":"Raje","year":"2014","journal-title":"Blood"},{"key":"41","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma","volume":"12","author":"Doyen","year":"2016","journal-title":"Blood"},{"key":"42","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1172\/JCI92504","article-title":"Pharmacological inhibition of the transcription factor PU.1 in leukemia","volume":"12","author":"Chen","year":"2017","journal-title":"J Clin Invest"},{"key":"43","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/bloodadvances.2017010348","article-title":"IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation","volume":"2","author":"Lentzsch","year":"2018","journal-title":"Blood Adv"},{"key":"44","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/bjh.15797","article-title":"Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma","volume":"18","author":"Gandhi","year":"2019","journal-title":"Br J Haematol"},{"key":"45","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"37","author":"Suvorov","year":"2015","journal-title":"N Engl J Med"},{"key":"46","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"37","author":"Ben Yehuda","year":"2016","journal-title":"N Engl J Med"},{"key":"47","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"37","author":"Beksac","year":"2015","journal-title":"N Engl J Med"},{"key":"48","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"38","author":"Dispenzieri","year":"2017","journal-title":"Lancet"},{"key":"49","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"38","author":"Perrot","year":"2019","journal-title":"N Engl J Med"},{"key":"50","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"1","author":"Cavo","year":"2013","journal-title":"Lancet Oncol"},{"key":"51","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/bjh.16213","article-title":"Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure","volume":"18","author":"Pierceall","year":"2020","journal-title":"Br J Haematol"},{"key":"52","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"2","author":"O\u2019Gorman","year":"2019","journal-title":"Lancet Oncol"},{"key":"53","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"37","author":"Jou","year":"2018","journal-title":"N Engl J Med"},{"key":"54","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/s0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"39","author":"Cavo","year":"2019","journal-title":"Lancet"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T15:23:44Z","timestamp":1626794624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":54,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2021,7,20]]}},"alternative-id":["27973"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27973","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]}}}